Clinical significance of Janus Kinase inhibitor selectivity
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2018/12/01
-
Journal
-
Indian UGC (journal)
-
Refrences59
-
Citations169
-
Ernest H Choy CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK
Cite
Choy, Ernest H. “Clinical Significance of Janus Kinase Inhibitor Selectivity”. Rheumatology, vol. 58, no. 6, 2018, pp. 953-62, https://doi.org/10.1093/rheumatology/key339.
Choy, E. H. (2018). Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology, 58(6), 953-962. https://doi.org/10.1093/rheumatology/key339
Choy, Ernest H. “Clinical Significance of Janus Kinase Inhibitor Selectivity”. Rheumatology 58, no. 6 (2018): 953-62. https://doi.org/10.1093/rheumatology/key339.
Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2018;58(6):953-62.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the musculoskeletal system
Medicine
Medicine (General)
Refrences
Refrences Analysis
The category
Medicine: Medicine (General) 33
is the most frequently represented among the references in this article. It primarily includes studies from Annals of the Rheumatic Diseases The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician | Nature Reviews Rheumatology |
| 3 | 2024 |
| Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis | Dermatitis® |
| 4 | 2024 |
Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan | Alimentary Pharmacology & Therapeutics |
| 2024 | |
EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3 | Annals of the Rheumatic Diseases |
| 1 | 2024 |
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry | Annals of the Rheumatic Diseases |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 69
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition and was published in 2019. The most recent citation comes from a 2024 study titled One gene to rule them all – clinical perspectives of a potent suppressor of cytokine signaling – SOCS1. This article reached its peak citation in 2023, with 48 citations. It has been cited in 105 different journals, 29% of which are open access. Among related journals, the Rheumatology cited this research the most, with 9 citations. The chart below illustrates the annual citation trends for this article.